Medicamentos de actualidad = Drugs of today

• 

  Año 2004, Vol. 40, Número 1

  • How significant is the role of P-glycoprotein in drug absorption and brain uptake?

    Jiunn H. Lin

    pág. 5

    

  • Ocular side effects associated with isotretinoin

    Frederick W. Fraunfelder

    pág. 23

    

  • Bisphosphonate treatment for multiple myeloma

    Evangelos Terpos, Amin Rahemfulla

    pág. 29

    

  • Clinical use of sibutramine

    Donna H. Ryan

    pág. 41

    

  • Theophylline: Mechanism of action and use in asthma and chronic obstructive pulmonary disease

    Trevor T. Hansel, Rachel C. Tennant, Andrew J. Tan

    pág. 55

    

  • Highlights from the 45th Annual Meeting of the ASTRO

    Benjamin W. Corn

    pág. 71

    

  • Highlights from the 36th Annual Meeting of the ASN

    Aleix Cases

    pág. 81

    
• 

  Año 2004, Vol. 40, Número 2

  • Lipid-based formulations of amphotericin B

    Venkateswarlu Vobalaboina, Prabhakar Veerareddy

    

  • Everolimus: A proliferation signal inhibitor targeting primary causes of allograft dysfunction

    John M. Kovarik

    pág. 101

    

  • Ytrium-90-ibritumomab tiuxetan radioimmunotherapy: A new treatment approach for B-cell non-Hodgkin's lymphoma

    Thomas E. Witzig

    pág. 111

    

  • Escitalopram

    Pedro Delgado, Sarah Aronson

    pág. 121

    

  • The benefits of microarrays as tools for studying neuropsychiatric disorders

    Edna Grünblatt

    pág. 147

    

  • New additions to the intensive care armamentarium

    Gordon R. Bernard, Tood W. Rice

    pág. 157

    

  • The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders

    Roger A. Barker, Timothy P. Harrower

    pág. 171

    
• 

  Año 2004, Vol. 40, Número 3

  • The promise of thalidomide: evolving indications

    Swati Joglekar, Mark Levin

    pág. 197

    

  • The role of botulinum toxin in neurology

    Brigitte Schurch

    pág. 205

    

  • An update on the use of 5alpha-reductase inhibitors

    Charlotte L. Foley, Simon R.J. Bott, Iqbal S. Shergill

    pág. 213

    

  • Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension

    Marie M. Budev, Omar A. Minai, Alejandro C. Arroliga

    pág. 225

    

  • The treatment of cancer pain

    Konstantin V. Slavin, Elijm P. Tesoro, Jeffrey J. Mucksavage

    pág. 235

    

  • Use of pharmacogenetics to guide warfarin therapy

    Howard L. Mcleod, Deepak Voora, Charles Eby

    pág. 247

    

  • Enfuvirtide

    Jacob P. Lalezari, Andrew D. Luber

    pág. 259

    
• 

  Año 2004, Vol. 40, Número 4

  • The soluble tumor necrosis factor receptor etanercept: A new strategy for the treatment of autoimmune rheumatic disease

    Xavier Rabasseda, Patrick Cole

    pág. 281

    

  • Adverse effects of new antiepileptic drugs

    Filiz Onat, Çigdem Özkara

    pág. 325

    

  • Solifenacin: Treatment of overactive bladder

    Kim Chilman-Blair

    pág. 343

    

  • Role of dopamine D3 receptors in the addictive properties of ethanol

    Christian A. Heidbreder, Michela Andreoli, Clara Marcon

    pág. 355

    

  • Omalizumab: An effective anti-IgE treatment for allergic asthma and rhinitis

    pág. 367

    
• 

  Año 2004, Vol. 40, Número 5

  • Hereditary sensory neuropathies

    Michaela Auer-Grumbach

    pág. 385

    

  • Etoricoxib

    Alan K. Matsumoto, Paul F. Jr. Cavanaugh

    pág. 395

    

  • Levocetirizine: A new selective H1 receptor antagonist for use in allergic disorders

    James H. Day, Anne K. Ellis, Elizabeth Rafeiro

    pág. 415

    

  • Thiazolidinediones: A new class of drugs for the therapy of ischemia-reperfusion injury

    Yuji Naito, Toshikazu Yoshikawa

    pág. 423

    

  • Uridine phosophorylase: An important enzyme in pyrimidine metabolism and fluoropyrimidine activation

    Deliang Cao, Giuseppe Pizzorno

    pág. 431

    

  • The increase in risk of diabetes mellitus from exposure to second-generation antipsycotic agents

    Leslie L. Citrome

    pág. 445

    

  • Atomoxetine - Treatment of attention deficit hyperactivity disorder: Beyond stimulants

    David Michelson, Christine Thomason

    pág. 465

    
• 

  Año 2004, Vol. 40, Número 6

  • Eplerenone: A new selective aldosterone receptor antagonist

    Myron H. Weinberger

    pág. 481

    

  • Advances in molecular targets and chemotheraphy of tuberculosis

    Vishnu Ji Ram, Seema Kumari

    pág. 487

    

  • Vagus nerve simulation therapy

    James W. Wheless, James Baumgartner

    pág. 501

    

  • Drotrecogin alfa

    Peter E. Morris, Michael J. Raggio

    pág. 517

    

  • The management of fibromyalgia

    Daniel J. Clauw, Srinivas G. Rao

    pág. 539

    

  • Summary of the Expert Symposium at the 53rd Annual Scientific Sessions of the American College of Cardiology

    pág. 555

    
• 

  Año 2004, Vol. 40, Número 7

  • Ciclesonide: A novel inhaled corticosteroid for asthma

    Pandora Christie

    pág. 569

    

  • Genes and migraine

    Robert W. Baloh

    pág. 577

    

  • Evaluation of oral budesonide in the treatment of active distal ulcerative colitis

    Jeroen J. Kolkman, Helmut W. Möllmann, Anja Clara Möllmann

    pág. 589

    

  • Anticonvulsant drugs in the treatment of substance withdrawal

    Yasser Khazaal, Josef Hättenschwiler, Daniele Fabio Zullino

    pág. 603

    

  • Highlights from the Atorvastatin Landmark Program: Global Investigators Meeting III

    Prabirkumar Bandyopadhyay

    pág. 621

    

  • Rosiglitazone maleate/metformin hydrochloride: A new formulation therapy for type 2 diabetes

    Sandra L. Cox

    pág. 633

    
• 

  Año 2004, Vol. 40, Número 8

  • Dutasteride: A potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia

    Xavier Rabasseda

    pág. 649

    

  • Towards cannabis and cannabinoid treatment of multiple sclerosis

    Stephen D. Miller, J. Ludovic Croxford

    pág. 663

    

  • Epinastine hydrochloride for atopic disease

    Frederick W. Fraunfelder

    pág. 677

    

  • Memantine hydrochloride: Pharmacological and clinical profile

    Stephen M. Graham, Hans J. Möbius, Albrecht Stöffler

    pág. 685

    

  • Systemic treatment of advanced non-small cell lung cancer

    Joan H. Schiller, Anne M. Traynor

    pág. 697

    

  • Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease

    Changiz Geula, Sultan Darvesh

    pág. 711

    

  • Cancer gene therapy based on the abstracts on the 2003 ASCO meeting and recent publications

    C.M. Iqbal Ahmed

    pág. 723

    
• 

  Año 2004, Vol. 40, Número 9

  • The genetics of bulimia nervosa

    Cynthia M. Bulik, Federica Tozzi

    pág. 741

    

  • Fulvestrant: A new type of estrogen receptor antagonist for the treatment of advanced breast cancer

    Aman U. Buzdar

    pág. 751

    

  • Pharmacotherapy in lower back pain

    Kenneth C. Jackson Ii

    pág. 765

    

  • Duloxetine: A new serotonin/noradrenaline reuptake inhibitor for the treatment of depression

    Xavier Rabasseda

    pág. 773

    

  • Stroke prevention with losartan in the context of other antihypertensive drugs

    Steven G. Chrysant

    pág. 791

    
• 

  Año 2004, Vol. 40, Número 10

  • Gefitinib: Current status in the treatment of non-small cell lung cancer

    Adnan Tanovic, Vicente Alfaro

    pág. 809

    

  • Treatment of pain symptoms in irritable bowel syndrome patients

    Vishal Gupta, Baharak Moshiree, G. Nicholas Verne

    pág. 829

    

  • Quetiapine in bipolar disorder: increasing evidence of efficacy and tolerability

    Xavier Rabasseda, Patrick Cole

    pág. 837

    

  • Aprepitant: An oral NK, antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy

    Kelly Pendergrass, Richard Hargreaves, Kevin J. Petty

    pág. 853

    

  • Risk of breast cancer and breast cancer characteristics in women after treatment for Hodgkin lymphoma

    Dietlind L. Wahner-Roedler, Ivy A. Petersen

    pág. 865

    
• 

  Año 2004, Vol. 40, Número 11

  • Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator

    Kim A. Papp

    pág. 889

    

  • Atazanavir: A novel once-daily protease inhibitor

    Peter J. Piliero

    pág. 901

    

  • New cancer vaccine approaches

    Johanne M. Kaplan

    pág. 913

    

  • Gene therapy of brain tumor with endostatin

    Ryuichi Tanaka, Ryuya Yamanaka

    pág. 931

    

  • Teriparatide: A bone formation treatment for osteoporosis

    Erik F. Eriksen, Deborah A. Robins

    pág. 935

    

  • HIV vaccine candidates

    George Johnson, Tai Te Wu

    pág. 949

    
• 

  Año 2004, Vol. 40, Número 12

  • Alefacept: A novel biologic in the treatment of psoriasis

    Gerald G. Krueger, Clive M. Liu, Jeffrey K. Mckenna

    pág. 961

    

  • Antioxidant effects of statins

    Lynn L. Stoll, Michael L. Mccornick, Gerene M. Denning

    pág. 975

    

  • Genetics of breast cancer

    Sigurdur Ingvarsson

    pág. 991

    

  • Immunosuppressive regimens in lung transplant recipients

    Jaime Villanueva, Ashby Jordan, Sangeeta M. Bhorade

    pág. 1003

    

  • Tegaserod: A serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome

    Xavier Rabasseda, Patrick Cole

    pág. 1013

    

  • Cumulative General Index

    pág. 1031